Safety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid Tumors

Part of paid clinical trials in Aurora, Colorado.

Sponsor
Bristol-Myers Squibb
Study ID
NCT02472977
Phase
PHASE1/PHASE2
Status
Terminated

Conditions

  • Solid Tumor

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this study is to determine whether the combination of Ulocuplumab and Nivolumab is safe and effective in the treatment of pancreatic cancer and small cell lung cancer.

Key Dates

Start date
Jul 13, 2015
Status verified
Oct 2018
Primary completion
Jan 27, 2017
Completion
Jan 27, 2017

Study Design

Enrollment
61 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER

Arms

  • Active Comparator: BMS-936564 (Ulocuplumab) + Nivolumab, Tumor type arm (SCLC)
    Small cell lung cancer (SCLC)
  • Active Comparator: BMS-936564 (Ulocuplumab) + Nivolumab, Tumor type arm (PAC)
    Pancreatic cancer (PAC)

Primary Outcome Measure

Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and Immune-mediated AEs [ Time Frame: From first dose until date of last dose of ulocuplumab or nivolumab plus 100 days (assessed up to January 2017, approximately 18 months) ]

Locations (6)

FacilityCityStateZIPSite coordinators
University Of Colorado HospAuroraColorado80045-
Indiana University HealthIndianapolisIndiana46202-
Sidney Kimmel Comprehensive Cancer Center At Johns HopkinsBaltimoreMaryland21287-
Columbia University Medical Center (Cumc)New YorkNew York10032-
Memorial Sloan Kettering Cancer CenterNew YorkNew York10065-
Huntsman Cancer InstituteSalt Lake CityUtah84112-

Find similar trials in Aurora, CO

By research site
University Of Colorado Hosp· Aurora, COIndiana University Health· Indianapolis, INSidney Kimmel Comprehensive Cancer Center At Johns Hopkins· Baltimore, MDColumbia University Medical Center (Cumc)· New York, NYMemorial Sloan Kettering Cancer Center· New York, NYHuntsman Cancer Institute· Salt Lake City, UT

Related Studies